Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 May;23(5):809-811.
doi: 10.1038/mt.2015.56.

Moving forward toward a cure for hemophilia B

Thierry VandenDriessche  1 , Marinee K Chuah  2
Affiliations
Comment

Moving forward toward a cure for hemophilia B

Thierry VandenDriessche et al. Mol Ther. 2015 May.
No abstract available

PubMed Disclaimer

Comment on

  • Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
    Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. Nathwani AC, et al. N Engl J Med. 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309. N Engl J Med. 2014. PMID: 25409372 Free PMC article. Clinical Trial.

References

    1. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K.et al. (2008Effect of gene therapy on visual function in Leber's congenital amaurosis N Engl J Med 3582231–2239. - PubMed
    1. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F.et al. (2009Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial Lancet 3741597–1605.erratum, Lancet 2010;375: 30. - PMC - PubMed
    1. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL.et al. (2010Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration Mol Ther 18643–650. - PMC - PubMed
    1. Carpentier AC, Frisch F, Labbé SM, Gagnon R, de Wal J, Greentree S.et al. (2012Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase–deficient patients J Clin Endocrinol Metab 971635–1644. - PubMed
    1. Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G.et al. (2013Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial Gene Ther 20361–369. - PMC - PubMed

Publication types